An important quality attribute of a recombinant adeno-associated virus (rAAV) as a therapeutic vector is its infectivity. Current assays to quantify infectious rAAV rely on coinfection with a helper virus such as adenovirus (Ad), which requires helper virus preparation and introduces additional variability. A simple method that has high sensitivity and removes the need for helper virus would improve assay consistency and facilitate high-throughput applications such as rAAV producer cell line development. In this study, we describe a stable assay cell line that was generated by integrating the coding sequences for AAV Rep68 and Ad E4orf6 and DNA binding protein under the control of inducible promoters. The Rep68 protein expression was further modulated by a ligand-responsive destabilization domain. In several benchmarks, the cell line gave comparable titers with those obtained using a classical Ad coinfection method. The cell line was also used to titer vectors of multiple rAAV serotypes. This cell line has the potential to serve as an effective and robust tool for quantifying infectious rAAV titers to advance gene therapy vector biomanufacturing.
Get full access to this article
View all access options for this article.
References
1.
HeX, UripBA, ZhangZ, et al.Evolving AAV-delivered therapeutics towards ultimate cures. J Mol Med, 2021; 99(5):593–617; doi: 10.1007/s00109-020-02034-2
2.
ZeltnerN, KohlbrennerE, ClementN, et al.Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors. Gene Ther, 2010; 17(7):872–879; doi: 10.1038/gt.2010.27
3.
GaoG-P, QuG, FaustLZ, et al.High-titer adeno-associated viral vectors from a rep/cap cell line and hybrid shuttle virus. Hum Gene Ther, 1998; 9(16):2353–2362; doi: 10.1089/hum.1998.9.16-2353
4.
MertenO-W.Cell & gene therapy insights challenges and advances in viral vectors review AAV vector production: State of the art developments and remaining challenges. Cell Gene Ther Insights, 2016; 2(5):521–551; doi: 10.18609/cgti.2016.067
5.
WerlingNJ, SatkunanathanS, ThorpeR, et al.Systematic comparison and validation of quantitative real-time PCR methods for the quantitation of adeno-associated viral products. Hum Gene Ther Methods, 2015; 26(3):82–92; doi: 10.1089/hgtb.2015.013
6.
GrimmD, KernA, PawlitaM, et al.Titration of AAV-2 particles via a novel capsid ELISA: Packaging of genomes can limit production of recombinant AAV-2. Gene Ther, 1999; 6(7):1322–1330; doi: 10.1038/sj.gt.3300946
ZolotukhinS, ByrneBJ, MasonE, et al.Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther, 1999; 6(6):973–985; doi: 10.1038/sj.gt.3300938
9.
ZhenZ, EspinozaY, BleuT, et al.Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events. Hum Gene Ther, 2004; 15(7):709–715; doi: 10.1089/1043034041361262
10.
LockM, McGorrayS, AuricchioA, et al.Characterization of a recombinant adeno-associated virus type 2 reference standard material. Hum Gene Ther, 2010; 21(10):1273–1285; doi: 10.1089/hum.2009.223
11.
XiaoX, LiJ, SamulskiRJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998;72(3):2224; doi: 10.1128/JVI.72.3.2224-2232.1998
12.
FrançoisA, BouzelhaM, LecomteE, et al.Accurate titration of infectious AAV particles requires measurement of biologically active vector genomes and suitable controls. Mol Ther Methods Clin Dev, 2018; 10:223–236; doi: 10.1016/j.omtm.2018.07.004
13.
GonçalvesMAFV. Adeno-associated virus: From defective virus to effective vector. Virol J 2005;2(1):43; doi: 10.1186/1743-422X-2-43
14.
StrackerTH, CassellGD, WardP, et al.The Rep protein of adeno-associated virus type 2 interacts with single-stranded DNA-binding proteins that enhance viral replication. J Virol, 2004; 78(1):441–453; doi: 10.1128/jvi.78.1.441-453.2004
15.
WardP, DeanFB, O'DonnellME, et al.Role of the adenovirus DNA-binding protein in in vitro adeno-associated virus DNA replication. J Virol, 1998; 72(1):420–427; doi: 10.1128/jvi.72.1.420-427.1998
16.
MatsushitaT, ElligerS, ElligerC, et al.Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther, 1998; 5(7):938–945; doi: 10.1038/sj.gt.3300680
17.
FerrariFK, SamulskiT, ShenkT, et al.Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol, 1996; 70(5):3227–3234; doi: 10.1128/jvi.70.5.3227-3234.1996
18.
CarterBJ, Marcus-SekuraCJ, LaughlinCA, et al.Properties of an adenovirus type 2 mutant, Ad2d/807, having a deletion near the right-hand genome terminus: Failure to help AAV replication. Virology, 1983; 126(2):505–516; doi: 10.1016/S0042-6822(83)80008-7
19.
SchmidtM, AfioneS, KotinRM. Adeno-associated virus type 2 rep78 induces apoptosis through caspase activation independently of p53. J Virol 2000;74(20):9441; doi: 10.1128/JVI.74.20.9441-9450.2000
20.
QiaoC, WangB, ZhuX, et al.A novel gene expression control system and its use in stable, high-titer 293cell-based adeno-associated virus packaging cell lines. J Virol, 2002; 76(24):13015–13027; doi: 10.1128/jvi.76.24.13015-13027.2002
BurbachBJ, SrivastavaR, MedeirosRB, et al. Distinct regulation of integrin-dependent T cell conjugate formation and NF-κB activation by the adapter protein ADAP. J Immunol 2008;181(7):4840; doi: 10.4049/jimmunol.181.7.4840
23.
KärberG.Contribution to the treatment of pharmacological data [in German]. Naunyn-Schmiedebergs Arch Exp Pathol Pharm, 1931; 162(4):480–483; doi: 10.1007/BF01863914
24.
RamakrishnanMA.Determination of 50% endpoint titer using a simple formula. World J Virol, 2016; 5(2):85–86; doi: 10.5501/wjv.v5.i2.85
25.
BanaszynskiLA, ChenL-C, Maynard-SmithLA, et al.A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell, 2006; 126(5):995–1004; doi: 10.1016/j.cell.2006.07.025
26.
LeeZ, LuM, IrfanullahE, et al.Construction of an rAAV producer cell line through synthetic biology. ACS Synth Biol, 2022; 11(10):3285–3295; doi: 10.1021/acssynbio.2c00207
27.
MohiuddinI, LoilerS, ZolotukhinI, et al.Herpesvirus-based infectious titering of recombinant adeno-associated viral vectors. Mol Ther, 2005; 11(2):320–326; doi: 10.1016/j.ymthe.2004.08.030
28.
DobnikD, KogovšekP, JakominT, et al. Accurate quantification and characterization of adeno-associated viral vectors. Front Microbiol 2019;10:1570; doi: 10.3389/fmicb.2019.01570
29.
RumachikNG, MalakerSA, PoweleitN, et al.Methods matter: Standard production platforms for recombinant AAV produce chemically and functionally distinct vectors. Mol Ther Methods Clin Dev, 2020; 18:98–118; doi: 10.1016/j.omtm.2020.05.018
30.
El AndariJ, GrimmD. Production, processing, and characterization of synthetic AAV gene therapy vectors. Biotechnol J 2021;16(1):2000025; doi: 10.1002/biot.202000025
31.
GrimmD, LeeJS, WangL, et al.In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol, 2008; 82(12):5887–5911; doi: 10.1128/JVI.00254-08
32.
McDougaldDS, DuongTT, PalozolaKC, et al.CRISPR activation enhances in vitro potency of AAV vectors driven by tissue-specific promoters. Mol Ther Methods Clin Dev, 2019; 13:380–389; doi: 10.1016/j.omtm.2019.03.004
33.
BoutinS, MonteilhetV, VeronP, et al.Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using aav vectors. Hum Gene Ther, 2010; 21(6):704–712; doi: 10.1089/hum.2009.182
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
